Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial

Fig. 4

The cross-neutralizing antibody titers, along with the corresponding four-fold rise rate, against Omicron BA.2, BA.4, and BA.5 induced by the booster vaccination of NVSI-06-09, compared with those boosted with BBIBP-CorV. a The anti-BA.2, anti-BA.4, and anti-BA.5 neutralizing antibody titers at baseline and on day 14 after booster vaccination. Data are presented as GMTs and 95% CIs. b The corresponding four-fold rise rate of neutralizing antibodies from baseline and 95%CIs on day 14 after the booster. ****: p < 0.0001, ns not significant

Back to article page